Candel Therapeutics, INC. (CADL) SEC Filings — 2024
21 SEC filings for Candel Therapeutics, INC. (CADL) in 2024.
Filings
- Candel Therapeutics, INC. SC 13G Filing — SC 13G · Dec 17, 2024
- Candel Therapeutics Files 8-K: Material Agreement and Other Events — 8-K · Dec 13, 2024
- Candel Therapeutics Files 8-K — 8-K · Dec 11, 2024
- Candel Therapeutics Q3 2024 Update — 10-Q · Nov 14, 2024
- Candel Therapeutics Files 8-K — 8-K · Oct 28, 2024
- Candel Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 13, 2024
- Candel Therapeutics Reports Shareholder Vote — 8-K · Jun 28, 2024
- Candel Therapeutics Files Proxy Statement for Annual Meeting — DEF 14A · May 30, 2024
- Candel Therapeutics Files 8-K with Corporate Updates — 8-K · May 30, 2024
- Candel Therapeutics Files 8-K — 8-K · May 23, 2024
- Candel Therapeutics, Inc. Files 10-Q for Q1 2024 — 10-Q · May 14, 2024
- Candel Therapeutics Files 10-K/A Amendment for Fiscal Year Ended December 31, 2023 — 10-K/A · Apr 25, 2024
- Candel Therapeutics Files 8-K — 8-K · Apr 25, 2024
- Candel Therapeutics Partners with Bristol Myers Squibb for Cancer Trial — 8-K · Apr 11, 2024
- Candel Therapeutics Files 8-K — 8-K · Apr 9, 2024
- Candel Therapeutics Partners with Bristol Myers Squibb for Melanoma Trial — 8-K · Apr 4, 2024
- Candel Therapeutics, Inc. Files 2023 Annual Report (10-K) — 10-K · Mar 28, 2024
- Candel Therapeutics Files 8-K for Regulatory and Financial Updates — 8-K · Mar 6, 2024
- Candel Therapeutics Files 8-K on Feb 13, Details Undisclosed — 8-K · Feb 13, 2024
- Candel Therapeutics Amends Officer Compensation on Jan 12 — 8-K · Jan 12, 2024
- Candel Therapeutics Confirms Emerging Growth Status in 8-K Filing — 8-K · Jan 3, 2024